Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
epothilone b · 6 trials · 9 indications
Objective tumor response was defined by the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines assessed by radiologic techniques and/or physical examination.
tumor response was defined by the Response Evaluation Criteria in Solid Tumors (RECIST).
| Arm | Type | Description |
|---|---|---|
| EPO906 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| epothilone b | DRUG | - |
Inclusion Criteria Patients must meet the following criteria to be eligible for the study: * Histologically or cytologically documented evidence of colorectal cancer with at least one measurable lesion (if previous radiation treatment, the target lesion must have demonstrated progression since the...
Epothilone B is an investigational small molecule being studied for the treatment of several solid tumors, including breast, ovarian, prostate, colorectal, kidney cancers, and melanoma. It is in Phase 2 clinical development for these oncology indications.
Epothilone B is being developed by Novartis AG, which trades on the New York Stock Exchange under the ticker symbol NVS. The drug is currently in Phase 2 clinical trials for multiple cancer indications.
Epothilone B is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials have been completed in patients with advanced ovarian, prostate, breast cancer, and melanoma.
Epothilone B has been studied in several completed Phase 2 trials, including NCT00035100 for ovarian, peritoneal, and fallopian tube cancer; NCT00035113 for prostate cancer; NCT00035126 for breast cancer; and NCT00035165 for melanoma. These trials enrolled adult patients.
Yes, epothilone B is also known as EPO906. Clinical trials for this drug, such as NCT00035100 and NCT00035126, refer to it as EPO906 therapy in their titles.